- Patient Selection Takes Priority as Standard of Cares Shift in HR+ and HER2+ Breast Cancerby OncLive articles on June 23, 2024
Lauren E. Nye, MD, discusses the use of CDK4/6 inhibitors in HR-positive metastatic breast cancer and the evolution of ADCs in HER2-positive disease.
- Lucio N. Gordan, MD, Discusses Findings of Phase 3 Clinical Trial Supporting Advanced Treatments for Multiple Myeloma in National Broadcastby OncLive articles on June 22, 2024
Lucio Gordan, MD, will join a panel to discuss treatment options for newly-diagnosed, transplant ineligible multiple myeloma.
- Garon Discusses the Standing and Future of ADCs, Targeted Therapies in NSCLCby OncLive articles on June 22, 2024
Edward B. Garon, MD, MS, takes stock of the non–small cell lung cancer field in light of recent updates from clinical trials.
- Dr Lenz on Frontline Nivolumab Plus Ipilimumab in MSI-H/dMMR mCRCby OncLive articles on June 21, 2024
Heinz-Josef Lenz, MD, FACP, discusses updated data for nivolumab plus ipilimumab in MSI-H/dMMR mCRC.
- Dr Yilmaz on HB-200 Arenavirus Plus Pembrolizumab in HPV16+ Head and Neck Cancerby OncLive articles on June 21, 2024
Emrullah Yilmaz, MD, PhD, discusses HB-200 arenavirus–based immunotherapy plus pembrolizumab in recurrent/metastatic HPV16+ head and neck cancer.
- Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancerby OncLive articles on June 21, 2024
First-line lenvatinib plus pembrolizumab demonstrated antitumor activity across various histologic subtypes in advanced or recurrent endometrial cancer.
- Dr Grimm on Post-Progression OS After Darolutamide Plus ADT/Docetaxel in mHSPCby OncLive articles on June 21, 2024
Marc-Oliver Grimm, MD discusses darolutamide in combination with androgen deprivation therapy and docetaxel in mHSPC.
- Dr Winer on the Rationale for the TakeAim Leukemia Trial in Mutated AMLby OncLive articles on June 21, 2024
Eric Winer, MD, discusses the rationale for the phase 1/2a TakeAim Leukemia trial of emavusertib in patients with R/R FLT3- and spliceosome-mutated AML.
- Dr Lai on NCCN Guideline Updates in AML Maintenance Therapyby OncLive articles on June 21, 2024
Catherine E. Lai, MD, MPH, discusses NCCN guideline updates regarding AML maintenance therapy, sharing how these updates influence treatment decisions.
- Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancerby OncLive articles on June 21, 2024
Durvalumab plus chemotherapy, followed by durvalumab maintenance with or without olaparib, improved responses in advanced endometrial cancer.
- Dr Braun on Biopsy Site Selection in Biomarker Testing in ccRCCby OncLive articles on June 21, 2024
David Braun, MD, PhD, discusses findings from the molecular analysis of the HCRN GU16-260-Cohort A study.
- Dr Maluf on Pembrolizumab Plus Platinum-Based Chemotherapy in Advanced Penile Cancerby OncLive articles on June 21, 2024
Fernando C. Maluf, MD, PhD discusses the efficacy of platinum-based chemotherapy plus pembrolizumab in advanced penile squamous cell carcinoma.
- Dr Al Malki on Outcomes With PTCy-Based GVHD Prophylaxis in Hematologic Malignanciesby OncLive articles on June 21, 2024
Monzr M. Al Malki, MD, discusses outcomes with mismatched unrelated donor transplantation using post-transplant cyclophosphamide–based GVHD prophylaxis.
- Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic Leukemiaby OncLive articles on June 21, 2024
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.
- Dr Jimenez Jimenez on PBSC from HLA-Mismatched Donors in Hematological Malignanciesby OncLive articles on June 21, 2024
Antonio Martin Jimenez Jimenez, MD, discusses conditioning therapy, PBSC from HLA-MMUD, and PTCy for GVHD prophylaxis in hematological malignancies.
- Safety Data With Ponatinib in PHALLCON for Ph+ Acute Lymphoblastic Leukemiaby OncLive articles on June 21, 2024
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss safety findings from the PHALLCON trial of ponatinib in Philadelphia chromosome–positive acute lymphoblastic leukemia.
- Clinical Efficacy With Ponatinib in the PHALLCON Trial for Ph+ ALLby OncLive articles on June 21, 2024
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the efficacy with ponatinib observed in the PHALLCON trial of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
- FDA Approves Adagrasib Plus Cetuximab for KRAS G12C–Mutant CRCby OncLive articles on June 21, 2024
The FDA has approved adagrasib plus cetuximab for patients with KRAS G12C–mutant locally advanced or metastatic colorectal cancer.
- The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALLby OncLive articles on June 21, 2024
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
- Current Standards of Care for Ph+ Acute Lymphoblastic Leukemiaby OncLive articles on June 21, 2024
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss current standards of care for the treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
- Prevalence and Prognosis of Ph+ Acute Lymphoblastic Leukemiaby OncLive articles on June 21, 2024
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the prevalence and prognostic outcomes of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
- Tucatinib-Based Regimen Improves Target Deficits, QOL in HER2+ Breast Cancer With Leptomeningeal Metastasisby OncLive articles on June 21, 2024
Patients with leptomeningeal metastasis from HER2-positive breast cancer experienced clinical benefit with tucatinib plus trastuzumab and capecitabine.